RGD Reference Report - Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis.

Authors: Domenicali, M  Caraceni, P  Giannone, F  Pertosa, AM  Principe, A  Zambruni, A  Trevisani, F  Croci, T  Bernardi, M 
Citation: Domenicali M, etal., Gastroenterology. 2009 Jul;137(1):341-9. Epub 2009 Jan 14.
RGD ID: 2314678
Pubmed: PMID:19208344   (View Abstract at PubMed)
DOI: DOI:10.1053/j.gastro.2009.01.004   (Journal Full-text)

BACKGROUND & AIMS: Endocannabinoids contribute to hemodynamic abnormalities of cirrhosis. Whether this favors renal sodium retention and ascites formation is unknown. We determined whether cannabinoid type 1 receptor antagonism prevents sodium retention and ascites formation in preascitic cirrhotic rats. METHODS: Once renal sodium handling was impaired, rats with carbon tetrachloride-induced cirrhosis were randomized to receive either vehicle or rimonabant (3 [group 1] or 10 [group 2] mg x kg(-1) x day(-1)) for 2 weeks. Natriuresis, sodium intake, and sodium balance were measured daily. At the end of the protocol, systemic hemodynamics, renal blood flow, ascites volume, and liver fibrosis were assessed. RESULTS: A significant reduction in ascites formation (group 1: 54%; group 2: 10%; vehicle: 90%) and volume (group 1: 1.6 +/- 0.3 mL; group 2: 0.5 mL; vehicle: 5.5 +/- 0.8 mL) occurred in treated rats. Rimonabant significantly improved sodium balance during week 2 (group 1: 0.98 +/- 0.08 mmol; group 2: 0.7 +/- 0.08 mmol; vehicle: 3.05 +/- 0.11 mmol). Both treated groups showed lower cardiac output and higher mean arterial pressure, peripheral vascular resistance, and renal blood flow (P < .05). Liver fibrosis was reduced in group 2 by 30% (P < .05 vs vehicle). Mean arterial pressure inversely correlated with sodium balance (R = -0.61; P = .003), but not with fibrosis score. CONCLUSIONS: Rimonabant improves sodium balance and delays decompensation in preascitic cirrhosis. This is achieved though an improvement in systemic and renal hemodynamics, although it cannot be excluded that the antifibrotic effect of the drug may play a role.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CNR1HumanAscites  ISOCnr1 (Rattus norvegicus)associated with Liver Cirrhosis and ExperimentalRGD 
Cnr1RatAscites  IMP associated with Liver Cirrhosis and ExperimentalRGD 
Cnr1MouseAscites  ISOCnr1 (Rattus norvegicus)associated with Liver Cirrhosis and ExperimentalRGD 

Objects Annotated

Genes (Rattus norvegicus)
Cnr1  (cannabinoid receptor 1)

Genes (Mus musculus)
Cnr1  (cannabinoid receptor 1)

Genes (Homo sapiens)
CNR1  (cannabinoid receptor 1)


Additional Information